Asundexian versus Apixaban in Patients with Atrial Fibrillation.
Jonathan P PicciniManesh R PatelJan SteffelKeith FerdinandIsabelle C Van GelderAndrea M RussoChang-Sheng MaShaun G GoodmanJonas OldgrenChristopher HammettRenato D LopesMasaharu AkaoRaffaele De CaterinaPaulus KirchhofDiana A GorogMartin HemelsMichiel RienstraW Schuyler JonesJosephine HarringtonGregory Yoke Hong LipStephen J EllisFrank W RockholdChristoph NeumannJohn H AlexanderThomas ViethenJames HungRosa CoppolecchiaHardi MundlValeria Casonull nullPublished in: The New England journal of medicine (2024)
Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the trial was stopped prematurely. There were fewer major bleeding events with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF ClinicalTrials.gov number, NCT05643573; EudraCT number, 2022-000758-28.).